Mountain Pacific Investment Advisers LLC Purchases 489 Shares of Eli Lilly and Company $LLY

Mountain Pacific Investment Advisers LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 137.7% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 844 shares of the company’s stock after purchasing an additional 489 shares during the period. Mountain Pacific Investment Advisers LLC’s holdings in Eli Lilly and Company were worth $658,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Madrona Financial Services LLC grew its holdings in Eli Lilly and Company by 9.0% during the 2nd quarter. Madrona Financial Services LLC now owns 389 shares of the company’s stock worth $303,000 after acquiring an additional 32 shares in the last quarter. SOA Wealth Advisors LLC. lifted its position in shares of Eli Lilly and Company by 56.6% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 17,781 shares of the company’s stock worth $13,861,000 after purchasing an additional 6,430 shares during the period. Parkwoods Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 13.9% during the second quarter. Parkwoods Wealth Partners LLC now owns 703 shares of the company’s stock valued at $548,000 after purchasing an additional 86 shares in the last quarter. Dogwood Wealth Management LLC increased its holdings in Eli Lilly and Company by 6.4% during the second quarter. Dogwood Wealth Management LLC now owns 1,016 shares of the company’s stock valued at $790,000 after buying an additional 61 shares during the period. Finally, First Pacific Financial raised its stake in Eli Lilly and Company by 57.1% in the second quarter. First Pacific Financial now owns 297 shares of the company’s stock worth $232,000 after buying an additional 108 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. JPMorgan Chase & Co. dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Morgan Stanley reiterated an “overweight” rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, HSBC raised shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and lifted their price objective for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $939.61.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $825.92 on Thursday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a market cap of $781.70 billion, a PE ratio of 53.98, a P/E/G ratio of 1.06 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business has a 50-day simple moving average of $733.71 and a two-hundred day simple moving average of $766.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. During the same period last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.